Zhejiang Medicine (600216) Fundamentals 2026 — P/E 15.5x, Revenue Analysis | SniperIQ
Zhejiang Medicine (600216) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥11.7B, trading at ¥12.21 on the SHH. This SniperIQ fundamentals page covers Zhejiang Medicine's valuation (P/E 15.5x, P/B 1.0x), profitability (net margin 8.5%), revenue (¥8.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Medicine's market cap?
Zhejiang Medicine (600216) has a market capitalization of approximately ¥11.7B, trading at ¥12.21 on the SHH. Market cap moves with the live share price.
What is Zhejiang Medicine's P/E ratio?
Zhejiang Medicine's trailing twelve-month P/E ratio is 15.5x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Medicine?
Zhejiang Medicine runs a net profit margin of 8.5%, a gross margin of 31.6%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Medicine generate?
Zhejiang Medicine reported revenue of ¥8.9B for fiscal year 2025, with net income of ¥873M and earnings per share (EPS) of 0.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Medicine pay a dividend?
Zhejiang Medicine offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Medicine financially healthy?
Zhejiang Medicine carries a debt-to-equity ratio of 0.07x and a current ratio of 3.39x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Medicine a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Medicine (600216) the key facts are: market cap ¥11.7B, P/E 15.5x, revenue ¥8.9B, 52-week range 10.94-18.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Medicine's full fundamentals live
Get Zhejiang Medicine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.